2011 Schedule
Thursday, July 21

8:30-10 a.m. Plenary session

PL-05 Plenary 5

PL-05-01 The Pathological Mechanisms Leading to Neurodegeneration and Cell Death in Frontotemporal Dementias
Manuela Nuemann, Institute of Neuropathology, University of Zurich, Zurich Switzerland

PL-05-02 APP, Tau And Presenilin: The Metal Ion Regulatory Proteins of Alzheimer's Disease
Ashley Bush, The Mental Health Research Institute of Victoria, Parkville, Victoria, Australia

PL-05-03 What Role Will Imaging Play in the New Diagnostic Criteria for Prodromal Alzheimer's Disease
Reisa Sperling, Brigham and Women's Hospital, Boston, Mass., United States

10-10:30 a.m. Break

10:30 a.m.-12:30 p.m. Invited Symposia and Featured Research Sessions

S5-01 Imaging Outcomes for Clinical Trials in Different Stages of AD
Chairs: Nick Fox, Dementia Research Centre, UCL Institute of Neurology, London, United Kingdom

Sandra Black, Sunnybrook Health Sciences Centre, Toronto, Canada

S5-01-01 Imaging for MCI/AD Trials: How to Do it?
Frederik Barkhof, Radiology and Image Analysis Centre (IAC), VU Medical Centre, Amsterdam, the Netherlands

S5-01-02 Going Earlier: Using Imaging to Power Studies for Clinical Disease "Prevention"
Jonathan Schott, Dementia Research Centre, University College London, Institute of Neurology, Queen Square, London, United Kingdom

S5-01-03 How Will Amyloid Imaging Really Be Used Inside and Outside Clinical Trials?
William J. Jagust, Helen Wills Neuroscience Institute, Berkeley, Calif., United States

S5-01-04 Counting Microbleeds for Alzheimer's Disease Immunotherapy: Is there a Safe Number for Inclusion and Continuation?
TBD

S5-01-05 Vasogenic Edema in Immunotherapy: Sign of Efficacy or Danger?
Stephen Salloway, Brown Medical School, Providence, R.I., United States

S5-01-06 Design Considerations for Presymptomatic Clinical Trials: The Alzheimer's Prevention Initiative Perspective Pierre Tariot, Banner Alzheimer's Institute, Phoenix, Ariz., United States